Aim: To investigate the potential antidepressant and anxiolytic effects of Neu-P11, a novel melatonin agonist, in two models of depression in rats and a model of anxiety in mice. Methods: In the learned helplessness test (LH), Neu-P11 or melatonin (25-100 mg/kg, ip) was administered to rats 2 h before the beginning of the dark phase once a day for 5 days and the number of escape failures and intertrial crossings during the test phase were recorded. In the forced swimming test (FST), rats received a single or repeated administration of Neu-P11 (25-100 mg/kg, ip). The total period of immobility during the test phase was assessed. In the elevated plus-maze test (EPM), mice were treated with Neu-P11 (25-100 mg/kg, ip) or melatonin in the morning or in the evening and tested 2 h later. The percentage of time spent in the open arms and the open arms entries were assessed. Results: In the LH test, Neu-P11 but not melatonin significantly decreased the escape deficit and had no effect on the intertrial crossings. In the FST, a single or repeated administration of Neu-P11, either in the morning or in the evening, significantly decreased the duration of immobility. In the EPM test, Neu-P11 significantly increased the percentage of time spent in the open arms and the open arms entries irrespective to the time of administration. Melatonin was effective only when administered in the afternoon.
Introduction
Depression is a serious mental disorder with a high prevalence worldwide. In the United States, depression affects about 17%-21% of the population [1] and costs over 83 billion dollars per year [2] . Depressed patients have an increased risk of suicide [3] , premature death [4] and other morbidity [5] . In recent years, there has been a dramatic increase in prescriptions of antidepressants that act by an interaction with serotonin and/or norepinepherine systems [6] . Antidepressants currently available produce tolerability and other safety related problems [7] , thus there is an unmet need for antidepressants with better efficacy and reduced side effects. Clinical and epidemiological studies suggest a strong association between sleep disorders and stress-related illnesses such as depression and anxiety [8] [9] [10] . After an early study found that depressed patients suffer from sleep disturbances (including a reduction in slow wave sleep, shortening of rapid eye movement sleep latency and increased rapid eye movement sleep) [11] , numerous subsequent studies confirmed that sleep disorders are commonly present together with depression [12] [13] [14] [15] . Sleep disturbances appear to be a major risk factor for depression [14] but the issue of whether sleep disorders have a causal role in depression remains to be resolved.
Melatonin is synthesized and secreted at night mainly by the pineal gland in vertebrates. Melatonin exerts its action by binding to the specific G protein-coupled receptors MT1 and MT2 which are widely distributed in the central nervous system [16] . There is increasing evidence that the timing of melatonin secretion is closely associated with the timing of sleep propensity [17] . Melatonin administration shifts circadian rhythms in both rodents [18] and humans [19] and improves sleep by shortening sleep latency and lengthening sleep duration [19] . Melatonin has been used successfully in treating insomnia [20] Antidepressant-and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models www.nature.com/aps Tian SW et al Acta Pharmacologica Sinica npg and various circadian rhythm disorders such as delayed sleep phase syndrome [21] and shift-work sleep disorder [22] . Melatonin and its agonists exert antidepressant-and/or anxiolytic effects in animal models [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . Clinical administration of melatonin or melatonin agonists has been effective in improving depressive symptoms [35, 36] . Several melatonin agonists have been developed with modified properties in comparison to melatonin. At present only two of the numerous synthesized ligands of melatonin receptors are of therapeutic importance: agomelatine (Valdoxan®) -for the treatment of depression and ramelteon (Rozerem®) -for the treatment of primary insomnia characterized by difficulty with sleep onset. Recent phase II and phase III studies have demonstrated that tasimelteon (VEC-162; a high affinity agonist of human MT1 and MT2 receptors) may have therapeutic potential for transient insomnia in circadian rhythm sleep disorders [37] . Neu-P11 [38] , a novel melatonin agonist, is currently in development for the treatment of insomnia. Neu-P11 binds with high affinity to melatonin receptors and exerts GABA enhancing properties [39] . Recent studies have shown that Neu-P11 promoted sleep [39] , inhibited weight gain and improved insulin sensitivity in high-fat/high-sucrose-fed rats [38] . In the present study we investigated the potential effects of Neu-P11 in two models of depression in rats and one model of anxiety in mice.
Materials and methods

Animals
Adult male Sprague Dawley rats (200-270 g) and 2-3 month old male Kunming mice were obtained from the Laboratory Animal Center of University of South China, Hengyang, Hunan, China. The rats were housed individually and the mice were housed in groups of 6 animals per cage in a temperature and humidity controlled environment with free access to food and water. The animals were maintained on a 12 h light/ dark schedule, with lights on at 7 AM. After being housed, the animals were handled (5-6 min per animal per day) for 1 week to habituate them to the experimenter. Experiments were conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and experimental protocols were approved by the University of South China Animal Care and Use Committee.
Drugs
Neu-P11 and melatonin were provided by Neurim Pharmaceuticals Ltd (Israel). Imipramine and diazepam were purchased from Sigma Co (St Louis, USA). Imipramine and diazepam were used as reference drug (positive control) for antidepressant and anxiolytic effects respectively. Neu-P11 and melatonin were homogenized in one drop of Tween-80 and diluted in sterile saline containing 1% dimethyl sulfoxide (vehicle) to the final volume immediately before administration. Imipramine and diazepam were dissolved in sterile saline immediately before administration.
Learned helplessness (LH) test in rats Apparatus and Procedure
The LH procedure involves two phases [24] : shock pretraining and avoidance-escape training. During the shock pretraining phase, the rats (12 per treatment group) in the helpless group were placed into fear conditioning chambers (Shanghai Jiliang Software Technology Co Ltd, Shanghai, China) as previously described [40, 41] and submitted to unsignalled inescapable foot shocks (0.8 mA, 15 s duration) given according to a variable time schedule with a mean interval of 60 s (ranging from 30-90 s) for 60 min. Thirty seconds after the final shock the rats were returned to their home cages. The rats in the non-helpless control (NHC) group were placed into the same chamber for 60 min but no shock was delivered during this time. During the avoidance-escape training phase (forty-eight hours after pretraining), all the rats were exposed to an avoidance-escape task in the automated two-way shuttle-boxes (Model, DCS-2; Institute of Materia Medica, Chinese Academy of Medical Sciences). Each box (64 cm×34 cm×24 cm) was divided into two compartments of equal size by a black Plexiglas partition containing an opening of 7×7 cm equipped with an electrified grid floor made of stainless steel rods. The rats were placed individually in the shuttle-box submitted to a test session. A 5 min environmental adaptation period was set before the beginning of 30 trials. A tone signal was presented for the first 5 s of each trial during which time the rats were allowed to avoid the shock (avoidance response). If no crossing occurred within this period, a footshock (8-second duration, 0.8 mA) was delivered. A single crossing from the electrified compartment to the other compartment made within this latter period was called an escape response. If no escape response occurred, tone and shock were turned off, and this was recorded as an escape failure (learned helplessness behavior). The shuttlebox test was repeated on day 4 and day 5, with no period of adaptation. During the test session, the number of escape failures and the number of intertrial crossings were recorded.
Experiment 1A
Experiment 1A was designed to assess the antidepressant effects of Neu-P11 in the LH model. Neu-P11 (25, 50, 100 mg/kg) and the reference compound imipramine (32 mg/kg) were administered ip repeatedly on 5 consecutive days (once per day). On day 1, Neu-P11 and imipramine were administered 6 h after the shock pretraining. On day 2-5, Neu-P11 was administered 2 h before the beginning of the dark phase, and imipramine was administered 60 min before the escape test. The same administration protocol was used for the administration of vehicle in the helpless control (HC) and NHC animals. Escape tests were performed in the morning on days 3-5.
Experiment 1B
Experiment 1B was designed to assess the antidepressantlike effects of melatonin in the LH model. In this experiment, training and drug administration schedule were as described www.chinaphar.com Tian SW et al Acta Pharmacologica Sinica npg in experiment 1A except that rats received melatonin (25, 50 , 100 mg/kg) instead of Neu-P11.
Forced swimming test (FST) in rats
Apparatus and procedure Four black Plexiglas cylinders were used for the FST. Each cylinder (height 40 cm, diameter 25 cm) was situated in a sound-attenuating cabinet which was located in an isolated room. Illumination was provided by a 15 W white house light mounted on the ceiling of cabinet, and a 65 dB background noise was supplied by a ventilation fan in the cabinet. The FST employed was similar to that described elsewhere [25] . Rats (12 per treatment group) were dropped individually into cylinders containing 20 cm of water maintained at about 25 °C and left for 15 min (pretest phase) or 5 min (test phase). The total period of immobility of each rat during the test phase was detected by a motion detector and analyzed by software provided by Shanghai Jiliang Software Technology Co Ltd, Shanghai, China.
Experiment 2A
Experiment 2A was designed to assess the antidepressant-like effects of single administration of Neu-P11 in the FST model. Vehicle, Neu-P11 (25, 50, 100 mg/kg) and imipramine (32 mg/ kg) were administered ip at about 8:00 AM or 22:00 PM, Each group was divided into two subgroups for the FST, (n=12 per subgroup). Twenty-four hours after an initial 15 min pretest, the subgroups were submitted to a 5 min test 2 and 12 hours after administration respectively. The FST was performed in the morning.
Experiment 2B
Experiment 2B was designed to assess the antidepressant effects of repeated administration of Neu-P11 in the FST model. The subgroups who had received drug injection 12 h before the test phase were used for testing the effects of repeated Neu-P11 administration. Vehicle, Neu-P11 (25, 50, 100 mg/kg) and imipramine (32 mg/kg) were injected repeatedly on 6 consecutive days (once per day) 2 h before the beginning of the dark phase. The FST was performed in the morning of day 7. [42] [43] [44] .
Experiment 3A Experiment 3A was designed to assess the dose-dependent anxiolytic effects of Neu-P11 in the EPM model. Vehicle, Neu-P11 (25, 50, 100 mg/kg) and the reference compound diazepam (2 mg/kg) were administered ip 2 h before the EPM test. The EPM test was performed in the morning.
Experiment 3B
Experiment 3B was designed to assess the time-dependent anxiolytic effects of Neu-P11 in the EPM model. Vehicle and Neu-P11 (50 mg/kg) were administered ip 30 min, 1 h, 2 h, or 3 h before the EMP test. The EPM test was performed in the morning.
Experiment 3C
Experiment 3C was designed to compare the effects of Neu-P11 to that of melatonin in the EPM model. Vehicle, Neu-P11 (50 mg/kg) and melatonin (50 mg/kg) were administered ip 2 h before the EMP test in the morning and in the afternoon respectively.
Statistical analyses
Statistical analyses were performed using one-way ANOVA or two-way ANOVA with or without repeated-measures (RM) (Sigma Stat 3.2). When a significant difference was found by two-way ANOVA a one-way ANOVA was performed. Post-hoc comparisons were performed with the Tukey HSD method. All data were represented as mean±SEM. Significant level was set at P<0.05.
Results
Learned helplessness test in rats Experiment 1A As shown in Figure 1A the HC rats presented an escape deficit on all 3 days of testing compared with the NHC rats. Imipramine treatment reversed the escape deficit observed in the HC rats over the 3 days of testing. The rats treated with Neu-P11 at 50 mg/kg showed a significant decrease of escape failures compared with HC animals over the 3 days of testing. We also found that compared with the HC rats, the rats treated with Neu-P11 at 25 mg/kg showed a significant decrease of escape failures on day 5. There was no significant difference in the level of escape failures between the rats treated with Neu-P11 at 100 mg/kg and the HC animals over all 3 days of testing. Only the NHC rats showed a significant increase in intertrial crossings over the 3 days of testing compared with HC animals ( Figure 1B ).
Experiment 1B
As observed in experiment 1A, compared with the NHC rats, the HC rats presented an escape deficit over all 3 days of test-www.nature.com/aps Tian SW et al Acta Pharmacologica Sinica npg ing, and imipramine treatment reversed the escape deficit observed in the HC rats over the 3 days of testing ( Figure  2A ). There was no significant difference in the level of escape failures between the rats treated with melatonin at any dose and the HC rats over all 3 days of testing. Only the NHC rats showed a significant increase in intertrial crossings compared with the HC rats on day 1 and 2 although this was not seen on day 3 ( Figure 2B ).
Forced swimming test (FST) in rats Experiment 2A
The effects of a single administration of Neu-P11 and imipramine are shown in Figure 3 . When drugs were administered 2 h before test phase ( Figure 3A) , the rats treated with Neu-P11 at 25, 50, and 100 mg/kg showed less levels of immobility time compared with the vehicle control rats. The positive control rats treated with imipramine also presented a similar decrease of the immobility time. When drugs were injected 12 hours before test phase ( Figure 3B ), the rats treated with Neu-P11 at 50 and 100 mg/kg and imipramine showed lower levels of immobility time compared with the vehicle control rats.
Experiment 2B
Repeated administration of Neu-P11 at 50 and 100 mg/kg significantly reduced the immobility time of rats compared with 
Elevated plus-maze (EPM) test in mice Experiment 3A
The dose-effects of Neu-P11 at 25, 50, and 100 mg/kg in the EPM test are shown in Figure 5 . Compared with the vehicle control the mice treated with Neu-P11 at 50 mg/kg and diazepam showed higher levels of the percentage of time spent in the open arms ( Figure 5A ). The mice treated with Neu-P11 at 50 and 100 mg/kg and diazepam showed higher levels of the percentage of the open arms entries compared with the vehicle control ( Figure 5B ). There was no significant difference among the five groups for the number of the closed arms entries (Figure 5C) .
Experiment 3B
The time-effects of 50 mg/kg Neu-P11 in the EPM test are shown in Figure 6 . Compared with the respective vehicle control the mice treated with Neu-P11 30 min, 1 h, 2 h or 3 h before the EPM test showed more time spent in the open arms ( Figure 6A ) and more open arms entries ( Figure 6B ). There was no significant effect of treatment for the number of the closed arms entries ( Figure 6C ).
Experiment 3C
The effects of Neu-P11 and melatonin, both at 50 mg/kg in the EPM test are shown in Figure 7 . Compared with the vehicle control the mice treated with Neu-P11 but not melatonin Figure 7B ). The mice treated with Neu-P11 presented higher levels of the open arms entries than mice treated with melatonin. both the mice treated with melatonin and Neu-P11 showed higher levels of the open arms entries compared with the vehicle control during the afternoon test. There was no significant effect of treatment for the number of the closed arms entries ( Figure 7C ).
Discussion
In the present study, we investigated the effects of Neu-P11 in two models of depression (LH and FST) in rats and one model of anxiety (EPM) in mice. Neu-P11 significantly decreased the level of escape failures in the LH model and reduced the duration of immobility in the FST model. In the EMP model, Neu-P11 significantly increased the percentage of the entries to and time spent in the open arms. The results suggest that Neu-P11 exerts antidepressant and anxiolytic activities in rodent models. Imipramine and diazepam were chosen as two positive reference compounds. Neu-P11 has been reported previously to decrease body weight gain and improve insulin sensitivity and metabolic profiles in obese rats at 10 mg/kg in 8-weeks study [38] . In this study, the observed decrease in body weight with Neu-P11 was ~5% in the first treatment week, similar to the effect of melatonin. It could be argued that Neu-P11-induced changes in body weight may produce a change in locomotor activity. However, our results did not support this argument. Melatonin appears to affect body weight of obese rats but did not affect body weight in normal rats [45] .
In the present study we tested normal rats or mice exposed to Neu-p11 and melatonin for a relatively short time (0-6 days). Our drug treatment procedure did not affect locomotor activity indexes, number of intertrial crossings and number of closed arm entries in the LH model and EPM model, respectively. We therefore surmise that the antidepressant and anxiolytic effects of Neu-P11 are unlikely to be attributed to a change in locomotor activity that followed Neu-P11 injection.
The dose response of Neu-P11 in the LH and EPM models appears to be bell-shaped. This explains why the 50 mg/kg dose appears to be superior to the 100 mg/kg. This phenomenon remains poorly understood although many of the most important biological events show receptor desensitization. The bell-shaped curve of Neu-P11 dose-response could be attributed either to down regulation of melatonin receptors by the high dose or cross talk of neu-P11 in high dose with other unidentified systems that might affect the behavior of the rats.
Previous studies have shown that the antidepressant activity of melatonin depend on the type of the animal model and experimental procedure adopted. Melatonin has induced antidepressant-like effects in the tail suspension [28] and chronic mild stress [31] models but not in the learned helplessness model [24] . In the forced swimming model, repeated [29, 33] but not single [25] administration of melatonin exerted antidepressant-like activities. A similar dependence was found for the anxiolytic-like activity of melatonin, for example melatonin was effective in the animal model for a 'trait' anxiety but not for a 'state' anxiety [32] . Melatonin also appeared only to be active in depression and anxiety models when administered in the afternoon or dark phase of the light/dark cycle [31, 32] . The present study demonstrated that the novel melatonin agonist Neu-P11 has antidepressant and anxiolytic properties similar to those of melatonin. Neu-P11 presented some activities distinguishable from those of melatonin. Neu-P11 was active persistently both in the LH and FST models. Neu-P11 activity was independent of the procedures of drug administration (single or repeated) in the FST test. Neu-P11 persistently displayed antidepressant properties (in the FST model) and anxiolytic properties in the EPM model whether administered during the morning or afternoon. The differential effects The exact mechanisms underlying the antidepressant and anxiolytic activities of melatonin agonists are not well established. In previous studies, γ-aminobutiric acid (GABA), serotonin (5-HT), glutamate and nitric oxide (NO) pathways have been indicated in brain melatonin effects [46] [47] [48] [49] . There is increasing evidence that melatonin is involved in the regulation of GABA-benzodiazepine receptor complex. Melatonin administration has been shown to modify GABA-benzodiazepine binding to brain membranes [50, 51] and increase of GABA turnover rate and GABA-induced chloride influx [52, 53] . In line with the GABAergic hypothesis of mental disorders, several reports have indicated that GABA-mimetic drugs have antidepressant and anxiolytic properties [26, 33, 54] and administration of a benzodiazepine receptor antagonist blunted melatonin activity [26, 33] . Recent evidence also shows that the antidepressant effect of melatonin could be mediated through an interaction with N-methyl-D-aspartate (NMDA) receptors and the L-arginine/NO pathway [55] . It is well documented that 5-HT neurotransmission is involved in anxiety and depression. Preclinical and clinical studies have shown that 5-HT 1A receptor agonists have antidepressant activity [56, 57] . Intracerebroventricular injection of mRNA antisense to 5-HT 2A receptors or systemic injection of a selective 5-HT 2A receptor antagonist produces antidepressant effects in rodent models [58, 59] . Agomelatine, a potent melatonin receptor agonist, also acts as an antagonist at 5-HT 2C receptors and exerts antidepressant activities in several animal models [23] [24] [25] 31] . Several antidepressants such as tricyclics, mianserin, mirtazapine and trazodone have been known to display moderate to high affinity for 5-HT 2C receptors [60, 61] . Melatonin has been shown to act as a 5-HT 2A antagonist [62] and regulates both spontaneous efflux and evoked release of 5-HT in the hippocampus [63] . These studies suggest that an interaction with the central serotonergic system is involved in the antidepressant and anxiolytic activities of melatonin and its analogues.
In summary we have demonstrated that Neu-P11, a novel melatonin agonist, exerts antidepressant and anxiolytic activities with persistent and time-independent characters in several rodent models. We suggest that these central nervous system effects of Neu-P11 are due to an interaction with central neurotransmitters such as GABA and 5-HT. Although the mechanisms by which Neu-P11 exerts its effects are under investigation, the current data suggest that Neu-P11 may serve as a novel agent for the treatment of affective disorders.
